Abstract
Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with an abysmal prognosis. Beyond the first-line setting, treatment for advanced PDAC is limited and suboptimal. Also, the efficacy of epidermal growth factor receptor (EGFR) targeted therapy alone in the chemo-refractory setting in PDAC tumors harboring druggable EGFR mutations is unclear. Here we describe the case of a patient with chemo-refractory advanced PDAC with an activating exon-19 EGFR mutation who had an exceptional response to erlotinib monotherapy.
Keywords:
Epidermal growth factor receptor; Exon-19 mutation; Pancreatic adenocarcinoma.
Copyright © 2021. Published by Elsevier Ltd.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Camptothecin / analogs & derivatives
-
Camptothecin / pharmacology
-
Camptothecin / therapeutic use
-
Carcinoma, Pancreatic Ductal / diagnosis
-
Carcinoma, Pancreatic Ductal / drug therapy*
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / pathology
-
Drug Resistance, Neoplasm / genetics
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Erlotinib Hydrochloride / pharmacology
-
Erlotinib Hydrochloride / therapeutic use*
-
Exons
-
Female
-
Fluorouracil / pharmacology
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / pharmacology
-
Leucovorin / therapeutic use
-
Middle Aged
-
Mutation
-
Neoplasm Staging
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / pathology
-
Proto-Oncogene Proteins p21(ras) / genetics
-
Treatment Outcome
Substances
-
KRAS protein, human
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors
-
Proto-Oncogene Proteins p21(ras)
-
Leucovorin
-
Fluorouracil
-
Camptothecin